Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of “Moderate Buy” by Analysts

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been assigned an average rating of “Moderate Buy” from the fourteen ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eleven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $13.60.

A number of research analysts recently weighed in on CMPX shares. Guggenheim reiterated a “buy” rating and issued a $12.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, March 24th. Canaccord Genuity Group dropped their target price on shares of Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, April 28th. Craig Hallum began coverage on shares of Compass Therapeutics in a research report on Friday, February 13th. They set a “buy” rating and a $15.00 price objective on the stock. Wall Street Zen cut Compass Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Finally, Raymond James Financial cut Compass Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 28th.

Compass Therapeutics Stock Performance

Shares of NASDAQ CMPX opened at $2.38 on Monday. The company has a market capitalization of $428.61 million, a P/E ratio of -5.80 and a beta of 0.89. Compass Therapeutics has a 52-week low of $1.61 and a 52-week high of $6.88. The company’s 50 day moving average price is $3.81 and its 200-day moving average price is $4.95.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). Analysts forecast that Compass Therapeutics will post -0.44 earnings per share for the current year.

Institutional Trading of Compass Therapeutics

Several institutional investors have recently added to or reduced their stakes in CMPX. Russell Investments Group Ltd. increased its holdings in shares of Compass Therapeutics by 3,933.7% in the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after buying an additional 7,592 shares during the period. Creative Planning bought a new stake in shares of Compass Therapeutics in the 2nd quarter valued at about $30,000. Flagship Harbor Advisors LLC purchased a new stake in Compass Therapeutics during the 4th quarter valued at about $32,000. Strs Ohio purchased a new stake in Compass Therapeutics during the 1st quarter valued at about $34,000. Finally, CIBC Bancorp USA Inc. bought a new position in Compass Therapeutics during the 3rd quarter worth approximately $37,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.